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world’s population, is characterized by inﬂammatory
liver lesions, steatosis and progressive ﬁbrosis of vari-
able intensity. Each year, 4–5% of chronic hepatitis C
patients develop cirrhosis and hepatocellular carcinoma
(HCC). Hepatitis C has become the main indication for
liver transplantation in industrialised countries and will
soon be the leading cause of HCC in Western Europe
[1]. Treatment options, which are based on interferon
treatment in combination with the nucleoside analogue
ribavirin, remain limited and treatment success varies
depending on the viral genotype.
Insulin resistance and type 2 diabetes are common
complications of all liver diseases, especially at the
advanced stage. Chronic hepatitis C virus (HCV) infec-
tion is associated with an increased risk of developing
glucose intolerance and diabetes and both clinical and
experimental observations suggest that HCV may
directly interfere with glucose homeostasis already at
early stages of infection [2–4]. HCV has been shown to
directly interfere with the insulin signaling pathway by
diﬀerent molecular mechanisms in a genotype dependent
manner, and all HCV genotypes have been reported to
induce insulin resistance. Furthermore, some studies
have reported positive correlations between the level of
insulin resistance and HCV replication levels [5–7,4].0168-8278/$36.00  2009 European Association for the Study of the Liver.
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E-mail address: Birke.Bartosch@inserm.frFor these reasons, insulin resistance is considered to be
an important determinant for the establishment and/or
maintenance of chronic HCV infection and its roles in
HCV replication and associated disease are therefore
important areas of research. The paper by Kasai et al.
[8] in this issue investigates the eﬀects HCV infection
on hepatic glucose signaling, which is closely linked to
insulin signaling cascades; the authors report that
HCV suppresses liver glucose uptake and correlate this
ﬁnding with downregulation or modulation of the cell
surface expression of the hepatic glucose transporters
GLUT1 and GLUT2.
Glucose is cleared from the bloodstream by a family
of facilitative transporters (GLUTs), which catalyze the
transport of glucose down its concentration gradient
and into cells of target tissues. Currently, several estab-
lished functional facilitative glucose transporter iso-
forms have been identiﬁed [9], but only two with
expression and activity in the liver. GLUT1 is ubiqui-
tously expressed, but present at particularly high levels
in human erythrocytes and in the endothelial cells of
barrier tissues such as the blood–brain barrier [10]. It
is responsible for the low-level of basal glucose uptake
required to sustain respiration in all cells. GLUT2 is a
low aﬃnity transporter for glucose. Its expression occurs
mainly in the liver, pancreas, kidney and in intestinal
absorptive epithelial cells where it is located in the baso-
lateral membrane. In the liver its expression levels have
been shown to directly correlate with blood glucose lev-
els. Thus, in hepatocytes, GLUT2 mediates inﬂux of
glucose from the blood into the liver, as well as eﬄux
of glucose that has been synthesized by gluconeogenesisPublished by Elsevier B.V. All rights reserved.
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additional pathways for uptake and eﬄux of newly
synthesized glucose into the blood have been put into
evidence, but remain to be identiﬁed [14,16,17]. Kasai
et al. [8] investigated the eﬀect of HCV infection on cel-
lular glucose transport and report that in the hepatoma
cell line Huh7.5, glucose uptake is reduced by 50 to 60%
either upon infection with HCV of genotype 2a or upon
introduction of genomic or subgenomic HCV replicons
of genotype 1b. The reduction in glucose uptake was
restored to wild-type levels upon elimination of HCV
virus or replicons from the cells via interferon treatment.
Thus reduction in glucose uptake seemed not only to be
speciﬁcally induced by HCV, but was observed to simi-
lar extents in the context of genotype 2a as well as 1b,
suggesting that the modulation of glucose transport by
HCV may be conserved across the diﬀerent HCV geno-
types. Kasai et al. [8] furthermore reported a reduced
surface staining of the glucose transporters GLUT1
and 2 in HCV replicon bearing cells. Upon infection
with HCV virus, GLUT2 surface expression levels also
signiﬁcantly decreased, while GLUT1 expression was
barely aﬀected, suggesting that in the context of an
infection, the inhibitory eﬀects of HCV on glucose
uptake are mainly mediated by changes in GLUT2 sur-
face expression. The authors demonstrate furthermore,
that reduced cell surface expression of GLUT2 and
GLUT1 was not due to proteasomal degradation, but
in the case of GLUT2 correlated well with a ca 2-fold
reduction of its mRNA levels. Transcription of the
GLUT2 gene returned to normal upon interferon treat-
ment, and the use of a reporter construct containing the
GLUT2 promoter further conﬁrmed a suppressive eﬀect
of HCV on GLUT2 transcription. GLUT1 transcription
was not modiﬁed by presence of HCV replicons or virus,
suggesting that the downregulation of GLUT1 from the
cell surface by HCV replicons occurs by modiﬁcation of
its intracellular localization. The authors were further-
more able to conﬁrm HCV-induced GLUT2 downregu-
lation in vivo. In liver biopsies from HCV infected
individuals GLUT2 speciﬁc immunostaining was
weaker than in livers from healthy patients. GLUT2
downregulation in vivo was also observed in liver biop-
sies from chronic hepatitis B patients.
In chronic hepatitis C, one important aspect of insu-
lin resistance is thought to be due to its regulatory eﬀect
on genes and pathways involved in lipogenesis [18–20].
Lipogenesis and concomitant stimulation of triglyceride
synthesis and storage in lipid droplets as well as
increased vLDL assembly and secretion are thought to
stimulate or even be required for the HCV assembly
process [21,22]. While SREBP-1c has emerged as a
major mediator of insulin action on cholesterol and lip-
ogenic gene regulation and is frequently found upregu-
lated in HCV infection, it is also required for
transcriptional activation of enzymes that convert glu-cose into glucose 6-phosphate (G6P). G6P is the precur-
sor for glycolysis, a process that provides carbon for
subsequent de novo lipid synthesis, but is also the form
in which glucose exerts its transcriptional activity.
Indeed transcription of glycolytic as well as lipogenic
genes such as acetyl CoA carboxylase (ACC) and fatty
acid synthase (FAS) has been shown to be regulated
by insulin signaling pathways/ SREBP-1c but also by
glucose [23]. Glucose stimulates lipogenesis by activat-
ing the glucose-responsive basic/helix-loop-helix/leucine
zipper transcription factor carbohydrate responsive ele-
ment binding protein (ChREBP). In particular, glucose
regulates the entry of ChREBP from the cytosol into
the nucleus in order to allow its interaction with carbo-
hydrate responsive elements (ChoRE) present in the
promoter regions of glycolytic and lipogenic genes
[24]. Indeed, ChREBP silencing in hepatocytes and mice
has been shown to cause a signiﬁcant reduction in lipid
synthesis [25]. Thus, ChREBP acts in synergy with
SREBP-1c in response to glucose and insulin, respec-
tively, to induce lipogenic genes such as FAS and ACC.
The downregulation of GLUT1 and GLUT2 by
HCV observed by Kasai et al. [8] raises the interesting
scenario, where HCV may modulate activity of lipogenic
enzymes not only by dys-regulating insulin signaling,
such as by modifying SREBP-1c induced transcription,
but also by dys-regulating glucose sensitive transcription
factors like ChREBP. The exact regulation of ChREBP
activation is not yet elucidated and it is thought that
besides glucose, additional factors stimulate its nuclear
translocation [26]. Indeed, the lipogenic activity of
ChREBP is also under control of protein kinase A,
AMP-activated protein kinase as well as protein phos-
phatase 2A [27], enzymes that in turn have been shown
to be modulated by HCV in a fashion that favors lipo-
genesis [6,28,29]. But how a cellular microenvironment
that favors lipogenesis, is compatible with an HCV-
induced decrease of intracellular glucose, raises the
important question where the carbon required for lipo-
genesis would originate from. While it remains to be
seen whether HCV-induced suppression of glucose
uptake in Huh7.5 cells holds true under more physiolog-
ically relevant conditions, such as in primary human
hepatocytes, overall not much is known regarding the
eﬃcacy of hepatic glucose uptake in insulin resistant
states. The study by Kasai et al. [8] in this issue certainly
adds a new level of complexity to the interactions of
HCV with the hepatic glucose and lipid metabolism,
and underlines their importance in the viral life cycle
and its potential pathogenic sequelae. The burning ques-
tions that remain are, whether GLUT2 downregulation
is a requirement for HCV replication and if so, what are
the consequences of GLUT2 downregulation on lipo-
genesis. It will furthermore be interesting to ﬁnd out
whether the previously reported association of GLUT2
with the insulin receptor [30] is of any importance in
B. Bartosch / Journal of Hepatology 50 (2009) 845–847 847these processes. Answers to these questions may help us
to delineate not only the molecular mechanisms underly-
ing HCV replication but will also help to elucidate the
roles of GLUTs in glucose and insulin signaling.
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